209
Views
27
CrossRef citations to date
0
Altmetric
Research Article

Human Exposure to Imidacloprid from Dogs Treated with Advantage®

, , &
Pages 287-291 | Received 01 Jul 2004, Accepted 15 Aug 2004, Published online: 09 Oct 2008
 

Abstract

The objective of this investigation was twofold: (1) to determine the transferable residue of imidacloprid in gloves worn while petting experimental household dogs after the application of Advantage® and (2) to determine the imidacloprid residue in the dog's blood. Advantage® contains 9.1% imidacloprid, which controls fleas on dogs for up to 30 days. Imidacloprid produces toxicity by interacting with nicotinic receptors. Advantage® (364 mg imidacloprid/dog) was applied topically to six household dogs. The glove and blood samples were collected at 24 h, 72 h, and then on a weekly basis for 5 weeks post-Advantage® application. The glove samples were collected by petting each dog for 5 minutes while wearing a different glove per dog. The blood samples (5 mL from each dog) were collected into EDTA tubes. The imidacloprid residue was determined in the blood extracts and glove samples using RP-HPLC. The highest levels of imidacloprid residues were detected at the 24-h interval in both glove (254.16 ± 25.49 ppm) and blood (54.06 ± 3.00 ppb) samples. The blood imidacloprid residue was reduced by one third at the 72-h interval (18.73 ± 2.00 ppb) and was not detected after 1 week. Imidacloprid residue in the glove samples decreased approximately one third between each collection interval. The residue of imidacloprid in the glove extract by the fourth week was very low (0.08 ± 0.02 ppm) and not detected by the fifth week. The present findings suggest that following topical application of Advantage®, imidacloprid residue can be detected in the dog's blood for up to 72 h, and transferable residue on the dog's coat can be detected for up to 4 weeks. Repeated chronic exposure to imidacloprid may pose possible health risks to veterinarians, veterinary technologists, dog caretakers, and owners.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.